Can Biologics Be Discontinued in Patients with Psoriatic Arthritis in Stable Remission? A Prospective Single-CenterClinical and Ultrasound Study

Table 1

Study population clinical characteristics on TP0 (baseline) vs. TP1 (disease relapse).

	TP0 (baseline)	TP1 (disease relapse)	Wilcoxon test
			value
BMI	27.4 (20.4–42.6)	27.8 (21.1–37.7)	0.045
BASDAI	0.5 (0.0–5.5)	3.8 (0.0–8.1)	<0.001
BASFI	0.1 (0.0–4.0)	1.8 (0.0–7.5)	<0.001
HAQ	0.0 (0.0–1.0)	0.5 (0.0–1.6)	<0.001
MASEI	25.0 (17.0–30.0)	26.0 (19.0–33.0)	<0.001
PASI	0.4 (0.0–2.1)	1.2 (0.0–9.6)	<0.001
DLQI	0.0 (0.0–3.0)	1.0 (0.0–16.0)	<0.001
CRP (mg/dl)	0.2 (0.1–1.0)	0.6 (0.1–2.1)	<0.001
ESR (mm/h)	11.0 (2.0–38.0)	20.0 (3.0–50.0)	<0.001
VAS pain	0.0 (0.0–30.0)	50.0 (0.0–100.0)	<0.001
VAS PGA	0.0 (0.0–20.0)	50.0 (0.0–100.0)	<0.001
TJC	0.0 (0.0–1.0)	3.0 (0.0–16.0)	<0.001
SJC	0.0 (0.0-0.0)	1.0 (0.0–16.0)	<0.001
LEI	0.0 (0.0-0.0)	0.0 (0.0–2.0)	<0.001

Data are expressed as median (range); BMI, body mass index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; MASEI, Madrid sonography enthesitis index; PASI, Psoriasis Area Severity Index; DLQI, Dermatology Life Quality Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale; PGA, patient-reported global health assessment; TJC/SJC, 66/68-swollen and tender joint counts; LEI, Leeds enthesitis index.